The online version of this article (doi:10.1186/1477-7819-10-146) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
All authors read and approved the final manuscript. JJ carried out the molecular studies. JMK interpreted the pathologic findings. YSH performed the operations. WPC carried out the data collection. KYL performed the operations and drafted the manuscript. SIA performed the operations. KCH performed the operations. ISP directed and interpreted the immunohistochemical stain.
Clusterin is known to be expressed in many human neoplasms, and is believed to participate in the regeneration, migration, and anti-apoptosis of tumor cells. However, few reports have addressed the relationship between the manifestation of clusterin and clinicopathologic parameters in pancreas cancer patients. In the present study, the authors investigated the expression of clusterin and its clinical significance in pancreatic adenocarcinoma.
Immunohistochemical staining was performed for clusterin in tumor tissues obtained from patients who received pancreatic resection with radical intent, and the associations of clusterin expression with various clinicopathologic parameters were analyzed in addition to the relation between its expression and survival.
Immunoreactivity for clusterin was observed in 17 of the 52 (33%) pancreatic adenocarcinomas examined. In addition, clusterin positivity was found to be associated with preoperative serum carcinoembryonic antigen level, perineural invasion, and, most strongly, lymph node metastasis. The survival analysis identified tumor differentiation and lymph node metastasis as the only significant prognostic factors.
Although not an independent prognostic factor, clusterin immunoreactivity can be used in conjunction with lymph node metastasis to predict survival in cases of pancreatic adenocarcinoma.
Sahin TT, Fujii T, Kanda M, Nagai S, Kodera Y, Kanzaki A, Yamamura K, Sugimoto H, Kasuya H, Nomoto S, Takeda S, Morita S, Nakao A: Prognostic implications of lymph node metastases in carcinoma of the body and tail of the pancreas. Pancreas. 2011, 40: 1029-1033. 10.1097/MPA.0b013e3182207893. CrossRefPubMed
Kanda M, Fujii T, Sahin TT, Kanzaki A, Nagai S, Yamada S, Sugimoto H, Nomoto S, Takeda S, Kodera Y, Morita S, Nakao A: Invasion of the splenic artery is a crucial prognostic factor in carcinoma of the body and tail of the pancreas. Ann Surg. 2010, 251: 483-487. 10.1097/SLA.0b013e3181cf9171. CrossRefPubMed
Kruger S, Ola V, Fischer D, Feller AC, Friedrich M: Prognostic significance of clusterin immunoreactivity in breast cancer. Neoplasma. 2007, 54: 46-50. PubMed
Yom CK, Woo HY, Min SY, Kang SY, Kim HS: Clusterin overexpression and relapse-free survival in breast cancer. Anticancer Res. 2009, 29: 3909-3912. PubMed
Toffanin S, Daidone MG, Miodini P, De Cecco L, Gandellini P, Cappelletti V: Clusterin: a potential target for improving response to antiestrogens. Int J Oncol. 2008, 33: 791-798. PubMed
Steinberg J, Oyasu R, Lang S, Sintich S, Rademaker A, Lee C, Kozlowski JM, Sensibar JA: Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res. 1997, 3: 1707-1711. PubMed
Chen Q, Wang Z, Zhang K, Liu X, Cao W, Zhang L, Zhang S, Yan B, Wang Y, Xia C: Clusterin confers gemcitabine resistance in pancreatic cancer. World J Surg Oncol. 2011, 24: 59-66. CrossRef
Bi J, Guo AL, Lai YR, Li B, Zhong JM, Wu HQ, Xie Z, He YL, Lv ZL, Lau SH, Wang Q, Huang XH, Zhang LJ, Wen JM, Guan XY: Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: a study on tissue microarrays. Neoplasma. 2010, 57: 191-197. 10.4149/neo_2010_03_191. CrossRefPubMed
- Clinical significance of clusterin expression in pancreatic adenocarcinoma
Won Pyo Cho
Kee Chun Hong
- BioMed Central
Neu im Fachgebiet Chirurgie
Mail Icon II